Charles River acquires Resero Analytics
Charles River Laboratories, a market-leader in the provision of analytic laboratory services for the biopharmaceutical and other industries, has announced its acquisition of Resero Analytics. Resero is a software company that specialises in providing software solutions for biopharma that help it harness its data. There are obvious synergies between the two companies, and as a result of the acquisition, Charles River will become “the exclusive contract research organisation (CRO) partner for TurboToxicology.”
Charles River Laboratories’ share price has appreciated 15% so far year to date
Source: Yahoo Finance
TurboToxicology analyses nonclinical data in a range of structured formats, conducting statistical analyses, applying propriety algorithms, and displaying study results in attractive user interfaces. It then “formats the data, in concert with the scientist’s interpretation, to generate a complete written report that is inclusive of text, tables, figures, and legends,” according to a press release over the acquisition.
In a statement, Charles Rivers’ corporate executive vice president for discovery and safety assessment, biologics testing solutions, and avian vaccine services, Birgit Girshick, said: “By implementing solutions that increase efficiency in reporting, our goal is to give our clients the gift of time. By alleviating some of the upfront administrative work, TurboToxicology’s report generation tool will allow time for greater focus on other areas of drug development.”
Dave Watson, PhD, MBA, Founder and CEO at Resero Analytics, added: “With a global network, and the most robust portfolio in preclinical research, Charles River was the clear CRO partner of choice for TurboToxicology.”
Dominion holds Charles River Laboratories in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.